| Gene ID | 348 |
| Symbol | APOE |
| Synonymous | AD2|APO-E|LDLCQ5|LPG |
| Full name | apolipoprotein E |
| Gene description | apolipoprotein E3 |
| Cytoband | 19q13.2 |
| Gene type | protein-coding |
| Synonymous | MIM:107741; HGNC:HGNC:613; Ensembl:ENSG00000130203; HPRD:00135; Vega:OTTHUMG00000128901 |
Pathways and Diseases | Detail |
|---|---|
Pathway | Lipoprotein metabolism;PID Reactome;500795 |
Pathway | HDL-mediated lipid transport;PID Reactome;500797 |
Pathway | Metabolism of lipids and lipoproteins;Reactome;REACT:22258 |
Pathway | Alzheimer's disease;KEGG PATHWAY;hsa05010 |
Pathway | Chylomicron-mediated lipid transport;PID Reactome;500796 |
Disease | Encephalopathies;FunDO |
Disease | Cardiovascular disease risk factors;NHGRI |
Disease | Lipoprotein glomerulopathy;OMIM |
Disease | Cardiovascular disease;FunDO |
Disease | differential expansion rates of small abdominal aortic aneurysms;GAD |
Disease | Psychomotor Agitation;GAD |
Disease | neuropathy, Alzheimer's disease related;GAD |
Disease | Vascular dementia;FunDO |
Disease | Down syndrome;FunDO |
Disease | Histiocytosis;FunDO |
Disease | Depression;FunDO |
Disease | Glaucoma;FunDO |
Disease | longevity;GAD |
Disease | life expectancy;GAD |
Disease | early onset ischemic heart disease.;GAD |
Disease | IMMUNE;GAD |
Disease | Parkinson's disease;GAD |
Disease | rapid motor decline;GAD |
Disease | schizophrenia;GAD |
Disease | Lupus Erythematosus, Systemic;GAD |
Disease | glaucoma;GAD |
Disease | Mycoses;FunDO |
Disease | PSYCH;GAD |
Disease | Psychotic disorder;FunDO |
Disease | nephropathy, diabetic;GAD |
Disease | Stroke;GAD |
Disease | cholesterol, HDL cholesterol, LDL;GAD |
Disease | quantitative traits;GAD |
Disease | Malaria;FunDO |
Disease | Inherited disorders of lipid/glycolipid metabolism;KEGG DISEASE |
Disease | cholesterol cholesterol, HDL cholesterol, LDL lipoprotein triglycerides;GAD |
Disease | Alzheimer disease-2;OMIM |
Disease | Hyperhomocysteinemia;FunDO |
Disease | lipoprotein;GAD |
Disease | type III hyperlipoproteinemia;GAD |
Disease | multiple sclerosis;GAD |
Disease | Infectious lung disease;FunDO |
Disease | memory decline;GAD |
Disease | familial dysbetalipoproteinemia;GAD |
Disease | C-reactive protein;GAD |
Disease | outcome after head injury;GAD |
Disease | apoA1;GAD |
Disease | Macular Degeneration;GAD |
Disease | Creutzfeldt-Jakob disease;GAD |
Disease | myocardial infarct;GAD |
Disease | dementia, vascular;GAD |
Disease | Ischemia;FunDO |
Disease | Alzheimer's disease (late onset);NHGRI |
Disease | Cholelithiasis;FunDO |
Disease | cardiovascular;GAD |
Disease | high coronary heart disease risk particularly affects ser;GAD |
Disease | hyperlipidemia;GAD |
Disease | cholesterol, total;GAD |
Disease | Brain imaging;NHGRI |
Disease | lipid metabolism disorders;GAD |
Disease | Liver cancer;FunDO |
Disease | Herpes;FunDO |
Disease | hypertension;GAD |
Disease | Hyperlipoproteinemia, type III;KEGG DISEASE;H00156 |
Disease | Dermatitis;FunDO |
Disease | cognitive function;GAD |
Disease | anticholinergic challenge-induced memory impairment;GAD |
Disease | coronary heart disease;GAD |
Disease | cardiovascular disease;GAD |
Disease | Subarachnoid hemorrhage;FunDO |
Disease | Cirrhosis;FunDO |
Disease | Epilepsy, Temporal Lobe;GAD |
Disease | Drug abuse;FunDO |
Disease | temporal lobe epilepsy;GAD |
Disease | sleep-disordered breathing;GAD |
Disease | diabetes, type 1;GAD |
Disease | Alzheimer's disease (late onset);GAD |
Disease | preeclampsia;GAD |
Disease | Coronary Disease;GAD |
Disease | triglycerides;GAD |
Disease | HDL cholesterol;GAD |
Disease | Confusion;GAD |
Disease | Learning disorder;FunDO |
Disease | Ovarian cancer;FunDO |
Disease | Alzheimer Disease;GAD |
Disease | Myocardial Infarction;GAD |
Disease | Severe type III hyperlipoproteinemia;GAD |
Disease | apolipoprotein E mutation [apolipoprotein E (delta149 Leu)];GAD |
Disease | persistent vegetative state;GAD |
Disease | Lupus erythematosus;FunDO |
Disease | Macular degeneration;FunDO |
Disease | LDL cholesterol;GAD |
Disease | cholesterol, HDL;GAD |
Disease | LDL cholesterol;NHGRI |
Disease | anti-atherogenic lipoprotein profile;GAD |
Disease | Brain imaging;GAD |
Disease | AGING;GAD |
Disease | Hypoglycemia;FunDO |
Disease | Rectum cancer;FunDO |
Disease | Prostate cancer;FunDO |
Disease | Polycystic kidney;FunDO |
Disease | psoriasis;GAD |
Disease | PHARMACOGENOMIC;GAD |
Disease | Dental plaque;FunDO |
Disease | Plasma Lipid Levels;GAD |
Disease | Autistic disorder;FunDO |
Disease | METABOLIC;GAD |
Disease | traumatic brain injury.;GAD |
Disease | warfarin sensitivity;GAD |
Disease | Genetic disorders;KEGG DISEASE |
Disease | Coronary Artery Disease;GAD |
Disease | CARDIOVASCULAR;GAD |
Disease | Glomerulonephritis;FunDO |
Disease | Hypertension/complications*;GAD |
Disease | serum lipids;GAD |
Disease | Stress disorder, post-traumatic;FunDO |
Disease | Traumatic Brain Imjury;GAD |
Disease | Neurodegenerative disorder;FunDO |
Disease | left-handedness and visuospatial skills;GAD |
Disease | Alzheimer's disease;KEGG DISEASE;H00056 |
Disease | Macular degeneration, age-related;OMIM |
Disease | C-reactive protein;NHGRI |
Disease | Gout;GAD |
Disease | selenium;GAD |
Disease | diabetic nephropathy;GAD |
Disease | aneurysmal subarachnoid hemorrhage;GAD |
Disease | Alzheimer's disease;GAD |
Disease | lipids;GAD |
Disease | carotid atherosclerosis;GAD |
Disease | diabetes, type 2;GAD |
Disease | Nervous system diseases;KEGG DISEASE |
Disease | premature coronary heart disease.;GAD |
Disease | obesity;GAD |
Disease | Breast cancer;FunDO |
Disease | apoB-100;GAD |
Disease | Amyotrophic lateral sclerosis;FunDO |
Disease | Embryoma;FunDO |
Disease | hypercholesterolemia;GAD |
Disease | Chronic simple glaucoma;FunDO |
Disease | Dementia;GAD |
Disease | VISION;GAD |
Disease | Rheumatoid arthritis;FunDO |
Disease | apoE;GAD |
Disease | Liver disease;FunDO |
Disease | Yersinia infection;FunDO |
Disease | cognitive ability;GAD |
Disease | Nephrosis;FunDO |
Disease | Bone Mineral Density;GAD |
Disease | Encephalitis;FunDO |
Disease | Diabetes mellitus;FunDO |
Disease | Alzheimer's disease;NHGRI |
Disease | bulbar-onset motor neuron disease;GAD |
Disease | Alzheimer`s Disease;GAD |
Disease | Drug-Induced dyskinesia;FunDO |
Disease | Cerebrovascular disorder;FunDO |
Disease | Kidney failure;FunDO |
Disease | Myocardial infarction susceptibility;OMIM |
Disease | Hyperlipoproteinemia, type III;OMIM |
Disease | NEUROLOGICAL;GAD |
Disease | glaucoma, primary open-angle;GAD |
Disease | Growth retardation;FunDO |
Disease | cholesterol, LDL;GAD |
Disease | cholesterol;GAD |
Disease | Hyperlipidemia;FunDO |
Disease | altered brain levels of apolipoprotein E;GAD |
Disease | Biliary cancer;FunDO |
Disease | endogenous hypertriglyceridemia and familial hypercholesterolemia;GAD |
Disease | Sea-blue histiocyte disease;OMIM |
Disease | Down Syndrome;GAD |
Disease | Neurodegenerative diseases;KEGG DISEASE |
Disease | cerebrovascular disease;GAD |
Disease | RENAL;GAD |
Disease | atherosclerosis, coronary;GAD |
Disease | arterial wall thickness;GAD |
Sequence Information | |
|---|---|
Nucleotide Sequence | >348 : length: 1316 GGGACAGGGGGAGCCCTATAATTGGACAAGTCTGGGATCCTTGAGTCCTACTCAGCCCCAGCGGAGGTGAAGGACGTCCTTCCCCAGGAGCCGGTGAGAAGCGCAGTCGGGGGCACGGGG ATGAGCTCAGGGGCCTCTAGAAAGAGCTGGGACCCTGGGAACCCCTGGCCTCCAGACTGGCCAATCACAGGCAGGAAGATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCA GGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTAC CTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAGGTCACCCAGGAACTGAGGGCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCG GAACTGGAGGAACAACTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTG CAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAG AAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGC TCCCTGGCCGGCCAGCCGCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCAGCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTG GCGGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAGAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGG GCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGAACGCCGAAGCCTGCAGCCATGCGACCCCACGCCACCCCGTGCCTCCTG CCTCCGCGCAGCCTGCAGCGGGAGACCCTGTCCCCGCCCCAGCCGTCCTCCTGGGGTGGACCCTAGTTTAATAAAGATTCACCAAGTTTCACGCATCAAAAAAAAAAAAAAAAAAA |
Protein Sequence | >348 : length: 343 MSSGASRKSWDPGNPWPPDWPITGRKMKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKS ELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVG SLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH |